Evidence map›Paper›PMID 34662181›Full record

ArticleAntimicrobial agents and chemotherapy2022

Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.

Louisa Warryn, Gerd Pluschke

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. The Mycobacterial cyt-Journal of medicinal chemistry · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Louisa WarrynSwiss Tropical and Public Health Institutegrid.416786.a, Basel, Switzerland.
Gerd PluschkeSwiss Tropical and Public Health Institutegrid.416786.a, Basel, Switzerland.ORCID 0000-0003-1957-2925
Swiss Tropical and Public Health Institute · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the treatment of chronic wounds, acid-oxidizing solutions (AOSs) with broad-spectrum microbicidal activity without disturbing granulation tissue formation have been developed. We found AOSs to efficiently kill Mycobacterium ulcerans, the causative agent of Buruli ulcer, which is able to survive harsh decontamination treatments. Topical AOS treatment of Buruli ulcer lesions may support the recommended antibiotic therapy (oral rifampin and clarithromycin), prevent contamination of the environment by the mycobacteria, and control secondary infections, which are a prevalent wound management problem in resource-poor settings where Buruli ulcer is endemic.

Indexed as

Buruli UlcerMycobacterium ulceransClarithromycinHumansOxidation-ReductionRifampinClarithromycinRifampinacid-oxidizing solutionBuruli ulcerMycobacterium ulceranswound management

Identifiers

PMID34662181
PMCPMC8765291
OpenAlexW3207557148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.